Core Insights - Castle Biosciences' DecisionDx-Melanoma test effectively identifies patients with less than 5% risk of sentinel lymph node (SLN) positivity, allowing them to safely forgo sentinel lymph node biopsy (SLNB) [1][2][3] - The DECIDE study demonstrated that all patients with a low-risk DecisionDx-Melanoma test result (Class 1A) were recurrence-free, indicating the test's reliability in predicting long-term outcomes [1][2][3] - The test significantly influences clinical decision-making, with 85% of SLNB decisions being affected by its results, thereby reducing unnecessary procedures and associated costs [2][3] Company Overview - Castle Biosciences, Inc. (Nasdaq: CSTL) focuses on innovative diagnostic tests that enhance patient care, with a portfolio that includes tests for skin cancers and other conditions [5][6] - The DecisionDx-Melanoma test has been ordered approximately 191,800 times for patients diagnosed with cutaneous melanoma, reflecting its widespread adoption and clinical relevance [4][6] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [5]
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test